- Home
- EML vs INBX Comparison
EML vs INBX Comparison
Compare EML & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | INBX |
|---|---|---|
| Founded | 1858 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EML | INBX |
|---|---|---|
| Price | $19.60 | $75.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 253.2K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $1,400,000.00 |
| Revenue This Year | $1.56 | $563.00 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.49 | $10.81 |
| 52 Week High | $29.55 | $94.57 |
Technical Indicators
Market Signals| Indicator | EML | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 43.34 |
| Support Level | $18.98 | $76.22 |
| Resistance Level | $20.70 | $81.79 |
| Average True Range (ATR) | 0.75 | 6.29 |
| MACD | 0.02 | -1.46 |
| Stochastic Oscillator | 31.37 | 4.28 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.